RARE - Company ID 0001515673
Ultragenyx Pharmaceutical Inc. trades as RARE and has a market capitalization of $3.40 B, making it the #1727 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $673.00M, up 20.2% from the prior year and net income of -$575.00M. This page tracks Ultragenyx Pharmaceutical Inc. through 1,100 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Ultragenyx Pharmaceutical Inc.'s revenue grew from $133.00K to $673.00M, a compound annual growth rate of 158.0%. Net profit margin expanded from -184867.7% to -85.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)—Ultragenyx Pharmaceutical Inc.
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference—Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)—Ultragenyx Pharmaceutical Inc.
The largest companies sharing Ultragenyx Pharmaceutical Inc.'s SEC industry classification (pharmaceutical preparations).
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $3.40 B as of 2026-07-09, ranking #1727 among US-listed companies.
Ultragenyx Pharmaceutical Inc. reported revenue of $673.00M for fiscal year 2025, an increase of 20.2% year over year.
In its latest fiscal year Ultragenyx Pharmaceutical Inc. reported a net loss of $575.00M.